|
Feb 18, 20:47
|
Firm-Record Nine Dean Omar Branham Shirley Attorneys Recognized for Plaintiff Consumer Law Excellence
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 20:46
|
Sector Update: Health Care Stocks Decline Late Afternoon
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 19:10
|
Johnson & Johnson Balances Oncology Breakthrough With Rising Talc Litigation Risk
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 16:17
|
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 15:44
|
Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 15:21
|
J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 15:15
|
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 14:15
|
Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 14:00
|
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 12:09
|
Is Kenvue (KVUE) Attractively Priced After Spin Off From Johnson & Johnson?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 10:32
|
XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 08:36
|
Johnson & Johnson Announce Breakthrough Therapy Designation From FDA For RYBREVANT In Non-Small Cell Lung Cancer
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 03:46
|
Trellus Health Extends Johnson & Johnson Collaboration Through Mid-2026 On Same Economic Terms After Achieving Key Engagement And Satisfaction Metrics
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 02:21
|
This State Has More Millionaires Per Capita Than Any Other
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 21:30
|
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 15:32
|
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 14:27
|
Beat the Market the Zacks Way: Micron Technology, Cooper Companies, Coeur Mining in Focus
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 13:57
|
AbbVie Down Since Q4 Earnings Report: How to Play the Stock
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 13:00
|
Behind the Scenes of Johnson & Johnson's Latest Options Trends
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 13:00
|
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 12:45
|
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner
|
N/A |
—
|
—
|
No analysis
|
|
Feb 16, 23:12
|
Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus
|
N/A |
—
|
—
|
No analysis
|
|
Feb 16, 19:11
|
What to Expect From These Drug/Biotech Players This Earnings Season?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 16, 14:55
|
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 14, 17:44
|
Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer
|
N/A |
—
|
✓
|
# JNJ News Report — 2026-02-14
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | JNJ |
| **Date** | 2026-02-14 |
| **Total Articles**...
|
|
Feb 13, 23:10
|
Johnson And Johnson Faces Legal Risks While Cardiac Data Supports Valuation
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 19:48
|
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 15:44
|
Pennsylvania Jury Finds Johnson & Johnson Liable For Woman's Ovarian Cancer - Attorney For National Talc Plaintiffs
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 15:09
|
Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:57
|
Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 10:19
|
H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 18:25
|
Pentair Just Paid Out: Is This Industrial Dividend Built to Last?
|
N/A |
—
|
✓
|
# JNJ News Report — 2026-02-12
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | JNJ |
| **Date** | 2026-02-12 |
| **Total Articles**...
|
|
Feb 12, 18:04
|
Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 10:02
|
enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 02:15
|
Johnson And Johnson Cardiac Data Fuels Fresh Look At Valuation Upside
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 20:13
|
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 18:29
|
Johnson & Johnson Files For Debt Shelf, Size Not Disclosed
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 16:14
|
Should You Buy ISRG Stock Despite a 13% Fall in Three Months?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 15:23
|
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 13:09
|
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 10:00
|
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 08:30
|
[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 00:17
|
How Recent Analyst Shifts Are Rewriting The Story For Johnson & Johnson (NYSE:JNJ)
|
N/A |
—
|
—
|
No analysis
|